Repligen Corporation (NASDAQ: RGEN) Stock Competitors & Peer Comparison
See RGEN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RGEN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGEN | $181.70 | +2.52% | 10.3B | 100.94 | $1.80 | N/A |
| ISRG | $391.95 | -2.32% | 138.5B | 40.74 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $176.80 | -0.71% | 48.7B | 13.60 | $13.00 | +2.25% |
| RMD | $218.89 | -1.02% | 31.8B | 20.33 | $10.77 | +1.12% |
| MDLN | $35.61 | +1.92% | 30.1B | 26.09 | $1.36 | N/A |
| WST | $364.98 | -0.01% | 25.7B | 42.94 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.85 | +0.09% | 15.2B | 12.37 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RGEN vs ISRG Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ISRG has a market cap of 138.5B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ISRG trades at $391.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ISRG's P/E ratio is 40.74. In terms of profitability, RGEN's ROE is +0.02%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, RGEN is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RGEN vs BDXA Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
RGEN vs BDX Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BDX has a market cap of 48.7B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BDX trades at $176.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BDX's P/E ratio is 13.60. In terms of profitability, RGEN's ROE is +0.02%, compared to BDX's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
RGEN vs RMD Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, RMD has a market cap of 31.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while RMD trades at $218.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas RMD's P/E ratio is 20.33. In terms of profitability, RGEN's ROE is +0.02%, compared to RMD's ROE of +0.24%. Regarding short-term risk, RGEN is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
RGEN vs MDLN Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, MDLN has a market cap of 30.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while MDLN trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas MDLN's P/E ratio is 26.09. In terms of profitability, RGEN's ROE is +0.02%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RGEN is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RGEN vs WST Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while WST trades at $364.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas WST's P/E ratio is 42.94. In terms of profitability, RGEN's ROE is +0.02%, compared to WST's ROE of +0.19%. Regarding short-term risk, RGEN is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RGEN vs HOLX Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGEN's ROE is +0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGEN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
RGEN vs SOLV Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while SOLV trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas SOLV's P/E ratio is 12.37. In terms of profitability, RGEN's ROE is +0.02%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, RGEN is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RGEN vs BDXB Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RGEN vs BAX Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BAX has a market cap of 12.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BAX trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BAX's P/E ratio is 11.29. In terms of profitability, RGEN's ROE is +0.02%, compared to BAX's ROE of -0.17%. Regarding short-term risk, RGEN is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RGEN vs COO Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, COO has a market cap of 11.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while COO trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas COO's P/E ratio is 12.48. In terms of profitability, RGEN's ROE is +0.02%, compared to COO's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
RGEN vs AVTR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while AVTR trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas AVTR's P/E ratio is 18.04. In terms of profitability, RGEN's ROE is +0.02%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGEN is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
RGEN vs ATR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ATR trades at $119.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ATR's P/E ratio is 20.97. In terms of profitability, RGEN's ROE is +0.02%, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RGEN vs BLCO Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BLCO trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BLCO's P/E ratio is 26.31. In terms of profitability, RGEN's ROE is +0.02%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGEN is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RGEN vs STVN Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, STVN has a market cap of 5.5B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while STVN trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas STVN's P/E ratio is 30.55. In terms of profitability, RGEN's ROE is +0.02%, compared to STVN's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
RGEN vs TFX Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while TFX trades at $124.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas TFX's P/E ratio is 14.19. In terms of profitability, RGEN's ROE is +0.02%, compared to TFX's ROE of -0.32%. Regarding short-term risk, RGEN is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RGEN vs MMSI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while MMSI trades at $85.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas MMSI's P/E ratio is 21.83. In terms of profitability, RGEN's ROE is +0.02%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RGEN vs ICUI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ICUI has a market cap of 4B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ICUI trades at $159.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ICUI's P/E ratio is 19.90. In terms of profitability, RGEN's ROE is +0.02%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, RGEN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
RGEN vs NVST Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NVST has a market cap of 3.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NVST trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NVST's P/E ratio is 15.96. In terms of profitability, RGEN's ROE is +0.02%, compared to NVST's ROE of +0.03%. Regarding short-term risk, RGEN is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RGEN vs PLSE Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while PLSE trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas PLSE's P/E ratio is -40.59. In terms of profitability, RGEN's ROE is +0.02%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, RGEN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RGEN vs ATRC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ATRC trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ATRC's P/E ratio is 1712.42. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RGEN is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RGEN vs BLFS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BLFS trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BLFS's P/E ratio is 36.21. In terms of profitability, RGEN's ROE is +0.02%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RGEN is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RGEN vs LMAT Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while LMAT trades at $78.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas LMAT's P/E ratio is 29.03. In terms of profitability, RGEN's ROE is +0.02%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGEN is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
RGEN vs AZTA Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while AZTA trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas AZTA's P/E ratio is 92.26. In terms of profitability, RGEN's ROE is +0.02%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RGEN is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AZTA's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RGEN vs XRAY Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while XRAY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas XRAY's P/E ratio is 6.06. In terms of profitability, RGEN's ROE is +0.02%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, RGEN is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RGEN vs KMTS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while KMTS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas KMTS's P/E ratio is -10.35. In terms of profitability, RGEN's ROE is +0.02%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, RGEN is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
RGEN vs STAA Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while STAA trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas STAA's P/E ratio is 39.42. In terms of profitability, RGEN's ROE is +0.02%, compared to STAA's ROE of +0.01%. Regarding short-term risk, RGEN is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
RGEN vs ATRI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGEN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RGEN vs ANGO Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ANGO has a market cap of 624.5M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ANGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ANGO's P/E ratio is -38.74. In terms of profitability, RGEN's ROE is +0.02%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RGEN is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
RGEN vs EMBC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, EMBC has a market cap of 335.2M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while EMBC trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas EMBC's P/E ratio is 2.17. In terms of profitability, RGEN's ROE is +0.02%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RGEN is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RGEN vs SMTI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, SMTI has a market cap of 320.4M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while SMTI trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas SMTI's P/E ratio is -580.83. In terms of profitability, RGEN's ROE is +0.02%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RGEN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RGEN vs OSUR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, OSUR has a market cap of 273M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas OSUR's P/E ratio is -5.75. In terms of profitability, RGEN's ROE is +0.02%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check OSUR's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RGEN vs NNNN Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NNNN has a market cap of 243.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NNNN trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NNNN's P/E ratio is 37.00. In terms of profitability, RGEN's ROE is +0.02%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGEN is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NNNN's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RGEN vs UTMD Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, UTMD has a market cap of 236M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while UTMD trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas UTMD's P/E ratio is 21.93. In terms of profitability, RGEN's ROE is +0.02%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RGEN vs PDEX Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, PDEX has a market cap of 204.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while PDEX trades at $64.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas PDEX's P/E ratio is 15.51. In terms of profitability, RGEN's ROE is +0.02%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, RGEN is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RGEN vs KRMD Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, KRMD has a market cap of 136M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while KRMD trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas KRMD's P/E ratio is -74.00. In terms of profitability, RGEN's ROE is +0.02%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RGEN is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
RGEN vs STXS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, STXS has a market cap of 115.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while STXS trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas STXS's P/E ratio is -6.94. In terms of profitability, RGEN's ROE is +0.02%, compared to STXS's ROE of -1.33%. Regarding short-term risk, RGEN is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RGEN vs AKYA Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGEN's ROE is +0.02%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGEN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
RGEN vs DXR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, DXR has a market cap of 61.9M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while DXR trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas DXR's P/E ratio is 8.63. In terms of profitability, RGEN's ROE is +0.02%, compared to DXR's ROE of +0.13%. Regarding short-term risk, RGEN is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
RGEN vs STSS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to STSS's ROE of -1.54%. Regarding short-term risk, RGEN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RGEN vs OMIC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGEN's ROE is +0.02%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGEN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RGEN vs IGAP Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGEN's ROE is +0.02%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RGEN is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RGEN vs POCI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, POCI has a market cap of 48.8M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while POCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas POCI's P/E ratio is -9.70. In terms of profitability, RGEN's ROE is +0.02%, compared to POCI's ROE of -0.24%. Regarding short-term risk, RGEN is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
RGEN vs NEPH Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NEPH has a market cap of 40.1M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NEPH trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NEPH's P/E ratio is 61.50. In terms of profitability, RGEN's ROE is +0.02%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RGEN is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NEPH's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RGEN vs HBIO Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, HBIO has a market cap of 36.7M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while HBIO trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas HBIO's P/E ratio is -22.58. In terms of profitability, RGEN's ROE is +0.02%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RGEN is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RGEN vs MLSS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, MLSS has a market cap of 33.5M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while MLSS trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas MLSS's P/E ratio is -7.57. In terms of profitability, RGEN's ROE is +0.02%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RGEN is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RGEN vs SDC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGEN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
RGEN vs IVC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGEN's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGEN is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RGEN vs RVP Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, RVP has a market cap of 21M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while RVP trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas RVP's P/E ratio is -5.83. In terms of profitability, RGEN's ROE is +0.02%, compared to RVP's ROE of -0.05%. Regarding short-term risk, RGEN is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
RGEN vs BNGO Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, BNGO has a market cap of 17.2M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while BNGO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas BNGO's P/E ratio is -0.50. In terms of profitability, RGEN's ROE is +0.02%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, RGEN is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RGEN vs ZJYL Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ZJYL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, RGEN's ROE is +0.02%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
RGEN vs RGNT Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, RGNT has a market cap of 12.7M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas RGNT's P/E ratio is -0.07. In terms of profitability, RGEN's ROE is +0.02%, compared to RGNT's ROE of N/A. Regarding short-term risk, RGEN is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
RGEN vs CUPR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, CUPR has a market cap of 6.5M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while CUPR trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas CUPR's P/E ratio is -1.75. In terms of profitability, RGEN's ROE is +0.02%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, RGEN is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
RGEN vs FEMY Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, FEMY has a market cap of 6.3M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while FEMY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas FEMY's P/E ratio is -0.46. In terms of profitability, RGEN's ROE is +0.02%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RGEN is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
RGEN vs LUCY Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, LUCY has a market cap of 5.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while LUCY trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas LUCY's P/E ratio is -0.69. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RGEN is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RGEN vs NSTG Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGEN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RGEN vs POAI Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas POAI's P/E ratio is -0.38. In terms of profitability, RGEN's ROE is +0.02%, compared to POAI's ROE of -21.19%. Regarding short-term risk, RGEN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RGEN vs MHUA Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGEN's ROE is +0.02%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RGEN vs GMVD Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RGEN vs GMVDW Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
RGEN vs AVGR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGEN's ROE is +0.02%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGEN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RGEN vs NXGL Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NXGL trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NXGL's P/E ratio is -0.25. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RGEN vs NXGLW Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RGEN is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RGEN vs LUCYW Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RGEN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
RGEN vs APR Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, APR has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas APR's P/E ratio is 22.59. In terms of profitability, RGEN's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, RGEN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
RGEN vs IIN Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGEN's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGEN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
RGEN vs ALOG Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGEN's ROE is +0.02%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RGEN vs ATRS Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGEN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
RGEN vs IVTY Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGEN's ROE is +0.02%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGEN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RGEN vs HRC Comparison October 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 10.3B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGEN is priced at $181.70 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 100.94, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGEN's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HRC's competition here